Stock Events

Stock Events

PolyPeptide Group 

€31.2
0
+€2.8+9.86% Thursday 06:10

Statistics

Day High
30.8
Day Low
30.8
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
May 22
€0.29
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12MarExpected
Q4 2024
Q2 2025
Q4 2025
-0.81
-0.44
-0.07
0.3
Expected EPS
0.295698748385
Actual EPS
N/A

Financials

-5.81%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
673.58MRevenue
-39.13MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8H0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bank of China
BACHF
Mkt Cap235.57B
Bachem Holding AG specializes in peptide technology, directly competing in the same sector as PolyPeptide.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. develops peptide therapeutics among other biotech solutions, overlapping with PolyPeptide's market.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company, through its acquisition of Prevail Therapeutics, competes in peptide drug development.
Novartis
NVS
Mkt Cap237.61B
Novartis AG engages in significant research in peptide-based drugs, competing for similar market share.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has investments in peptide research and drug development, positioning it as a competitor.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG develops peptide therapeutics, directly competing with PolyPeptide in the biopharmaceutical field.
Sanofi
SNY
Mkt Cap124.45B
Sanofi SA focuses on peptide drug solutions among its diverse biopharmaceutical products, competing with PolyPeptide.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. has a strong focus on innovative drug development including peptides, competing in the same arena.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc invests in peptide-based drug development, making it a competitor in this specialized field.

About

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Show more...
CEO
ISIN
CH1110760852
WKN
000A3CNHV

Listings

F
DE
8H0.F
LSE
GB
0AAJ.LSE
SW
CH
PPGN.SW
OTC Link
US
PLYGF

0 Comments

Share your thoughts

FAQ

What is PolyPeptide Group stock price today?▼
The current price of 8H0.F is €31.2 EUR — it has increased by +9.86% in the past 24 hours. Watch PolyPeptide Group stock price performance more closely on the chart.
What is PolyPeptide Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PolyPeptide Group stocks are traded under the ticker 8H0.F.
When is the next PolyPeptide Group earnings date?▼
PolyPeptide Group is going to release the next earnings report on August 13, 2026.
What is PolyPeptide Group revenue for the last year?▼
PolyPeptide Group revenue for the last year amounts to 673.58M EUR.
What is PolyPeptide Group net income for the last year?▼
8H0.F net income for the last year is -39.13M EUR.
Does PolyPeptide Group pay dividends?▼
Yes, 8H0.F dividends are paid annual. The last dividend per share was 0.29 EUR. As of today, Dividend Yield (FWD)% is 0%.
When did PolyPeptide Group complete a stock split?▼
PolyPeptide Group has not had any recent stock splits.